The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The correlation between the severity of cetuximab-induced rash and clinical outcome for patients with head and neck carcinoma treated with chemoradiotherapy (CRT) plus cetuximab: The RTOG experience.
Voichita Bar-Ad
No relevant relationships to disclose
Qiang Zhang
No relevant relationships to disclose
Paul M. Harari
No relevant relationships to disclose
Rita Axelrod
No relevant relationships to disclose
David Ira Rosenthal
No relevant relationships to disclose
Andy Trotti
No relevant relationships to disclose
Christopher U. Jones
No relevant relationships to disclose
Adam S. Garden
No relevant relationships to disclose
Guobin Song
No relevant relationships to disclose
Robert Leonard Foote
No relevant relationships to disclose
David Raben
No relevant relationships to disclose
George Shenouda
No relevant relationships to disclose
Sharon Spencer
No relevant relationships to disclose
Jonathan Harris
No relevant relationships to disclose
Quynh-Thu Le
No relevant relationships to disclose